CAMBRIDGE, Mass. - NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a biotech firm focusing on cardiometabolic diseases, has confirmed the appointment of Marshall Woodworth as the permanent Chief Financial Officer, Principal Financial (NASDAQ:PFG) Officer, and Principal Accounting Officer as of March 1, 2024.
Woodworth's transition from Acting Chief Financial Officer, a role he has held since October 27, 2023, follows a successful tenure.
The company's President and CEO, Hyung Heon Kim, expressed confidence in Woodworth's extensive experience in the pharmaceutical and medical device sectors, emphasizing his vital role in achieving NeuroBo's strategic goals.
Woodworth, reflecting on his appointment, shared his enthusiasm for the company's direction, particularly the upcoming clinical milestones.
With a background that includes CFO roles at Nevakar, Inc., Braeburn Pharmaceuticals, Inc., Aerocrine AB, and Furiex Pharmaceuticals Inc., Woodworth brings a wealth of experience to NeuroBo.
NeuroBo's current pipeline includes DA-1241, a GPR119 agonist aimed at treating MASH and Type 2 Diabetes Mellitus, and DA-1726, an oxyntomodulin analogue designed for obesity treatment. Both compounds have shown promise in preclinical studies, with DA-1241 impacting liver inflammation and glucose metabolism, and DA-1726 potentially offering superior weight loss due to its dual agonist properties.
The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.